Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) has seen a decline in its stock price by -10.43 in relation to its previous close of 48.50. However, the company has experienced a -15.73% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-01-10 that Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione
Is It Worth Investing in Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Right Now?
Company’s 36-month beta value is 0.59.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 5 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CRNX is 86.89M, and currently, short sellers hold a 7.20% ratio of that floaft. The average trading volume of CRNX on January 10, 2025 was 747.97K shares.
CRNX’s Market Performance
CRNX’s stock has seen a -15.73% decrease for the week, with a -23.28% drop in the past month and a -14.32% fall in the past quarter. The volatility ratio for the week is 3.92%, and the volatility levels for the past 30 days are at 4.47% for Crinetics Pharmaceuticals Inc The simple moving average for the past 20 days is -17.25% for CRNX’s stock, with a -15.01% simple moving average for the past 200 days.
Analysts’ Opinion of CRNX
Many brokerage firms have already submitted their reports for CRNX stocks, with Citigroup repeating the rating for CRNX by listing it as a “Buy.” The predicted price for CRNX in the upcoming period, according to Citigroup is $68 based on the research report published on March 06, 2024 of the previous year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see CRNX reach a price target of $50. The rating they have provided for CRNX stocks is “Overweight” according to the report published on January 16th, 2024.
Jefferies gave a rating of “Hold” to CRNX, setting the target price at $35 in the report published on December 21st of the previous year.
CRNX Trading at -21.54% from the 50-Day Moving Average
After a stumble in the market that brought CRNX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.53% of loss for the given period.
Volatility was left at 4.47%, however, over the last 30 days, the volatility rate increased by 3.92%, as shares sank -22.77% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -22.75% lower at present.
During the last 5 trading sessions, CRNX fell by -14.35%, which changed the moving average for the period of 200-days by +2.39% in comparison to the 20-day moving average, which settled at $52.53. In addition, Crinetics Pharmaceuticals Inc saw -15.04% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CRNX starting from Pizzuti Dana, who sale 15,000 shares at the price of $52.09 back on Jan 03 ’25. After this action, Pizzuti Dana now owns 29,248 shares of Crinetics Pharmaceuticals Inc, valued at $781,350 using the latest closing price.
DANA J PIZZUTI, the Officer of Crinetics Pharmaceuticals Inc, proposed sale 15,000 shares at $52.09 during a trade that took place back on Jan 03 ’25, which means that DANA J PIZZUTI is holding shares at $781,323 based on the most recent closing price.
Stock Fundamentals for CRNX
Current profitability levels for the company are sitting at:
- -295.87 for the present operating margin
- -0.43 for the gross margin
The net margin for Crinetics Pharmaceuticals Inc stands at -267.48. The total capital return value is set at -0.35. Equity return is now at value -40.26, with -35.20 for asset returns.
Currently, EBITDA for the company is -221.51 million with net debt to EBITDA at 0.87. When we switch over and look at the enterprise to sales, we see a ratio of 3562.27. The receivables turnover for the company is 0.15for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 16.38.
Conclusion
In a nutshell, Crinetics Pharmaceuticals Inc (CRNX) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
